目的　考察萘普生 (Nap)与其 β CD包合物间光谱特征的差异对光谱法分析测定的影响。 方法　通过化合物与包合物平衡溶液间吸收曲线的测试和斜率的比较 ,以确认作为光谱法分析时的参考标准 ,并用解络法进行验证 ;首次利用 β CD ,Nap以及包合物之间旋光度的差异确定了 β CD·Nap的组成比。 结果　证明光谱法测定主药Nap含量时 ,应制备同组成的包合物溶液做参考标准或将包合物解络后再以纯Nap做参考。结论　对于光谱特征变化明显的包合态药物的光谱法分析 ,均可先解络而后以游离形态以相应化合物做参考进行测定。 Objective To investigate the influence of the differences in spectral characteristics between naproxen and its β CD inclusion complex on spectroscopic analysis. The method was used to determine the absorbance curve of the solution and the equilibrium between the compound and the inclusion complex by comparing the slope of the absorption curve with that of the inclusion complex to confirm the reference standard for spectroscopic analysis and to verify it with the deconvolution method. The difference in degree determines the compositional ratio of β CD · Nap. The results show that spectrophotometry Nap content of the main drug should be prepared with the composition of the inclusion complex solution as a reference standard or after the inclusion complex solution network pure Nap reference. Conclusion For spectrophotometric analysis of clathrate drugs with obvious changes in spectral characteristics, the compounds can be dissociated and then measured in free form with reference to the corresponding compounds.